S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.16 (-0.15%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.14 (+0.18%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.68 (-15.21%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NASDAQ:CERT

Certara (CERT) Stock Price, News & Analysis

$17.98
+0.36 (+2.04%)
(As of 02:23 PM ET)
Today's Range
$17.70
$18.48
50-Day Range
$15.81
$19.45
52-Week Range
$11.81
$24.96
Volume
317,765 shs
Average Volume
526,235 shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.64

Certara MarketRank™ Stock Analysis

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
9.2% Upside
$19.64 Price Target
Short Interest
Bearish
4.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.75mentions of Certara in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$108,000 Sold Last Quarter
Proj. Earnings Growth
20.69%
From $0.29 to $0.35 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

142nd out of 938 stocks

Prepackaged Software Industry

29th out of 198 stocks

CERT stock logo

About Certara Stock (NASDAQ:CERT)

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Stock Price History

CERT Stock News Headlines

CERT Apr 2024 22.500 call
Schrodinger Inc.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
CERT Apr 2024 17.500 call
Q4 2023 Certara Inc Earnings Call
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Certara Reports Fourth Quarter 2023 Financial Results
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Certara Inc Ordinary Shares CERT
Certara Inc Ordinary Shares
Certara acquires Applied BioMath
See More Headlines
Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Prepackaged software
Sub-Industry
N/A
Current Symbol
NASDAQ:CERT
Fax
N/A
Employees
1,391
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.64
High Stock Price Target
$24.00
Low Stock Price Target
$15.50
Potential Upside/Downside
+7.8%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$-55,360,000.00
Pretax Margin
-15.56%

Debt

Sales & Book Value

Annual Sales
$354.34 million
Cash Flow
$1.00 per share
Book Value
$6.55 per share

Miscellaneous

Free Float
155,699,000
Market Cap
$2.91 billion
Optionable
Optionable
Beta
1.62
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


CERT Stock Analysis - Frequently Asked Questions

Should I buy or sell Certara stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Certara in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares.
View CERT analyst ratings
or view top-rated stocks.

What is Certara's stock price target for 2024?

10 Wall Street research analysts have issued 12-month target prices for Certara's stock. Their CERT share price targets range from $15.50 to $24.00. On average, they expect the company's share price to reach $19.64 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts price targets for CERT
or view top-rated stocks among Wall Street analysts.

How have CERT shares performed in 2024?

Certara's stock was trading at $17.59 at the start of the year. Since then, CERT shares have increased by 2.2% and is now trading at $17.98.
View the best growth stocks for 2024 here
.

Are investors shorting Certara?

Certara saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 5,280,000 shares, an increase of 12.6% from the February 29th total of 4,690,000 shares. Based on an average daily trading volume, of 529,000 shares, the days-to-cover ratio is currently 10.0 days. Approximately 4.8% of the company's shares are sold short.
View Certara's Short Interest
.

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our CERT earnings forecast
.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) issued its quarterly earnings results on Thursday, February, 29th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $0.04. The company earned $88.01 million during the quarter, compared to analyst estimates of $86.80 million. Certara had a positive trailing twelve-month return on equity of 4.33% and a negative net margin of 15.62%.

What guidance has Certara issued on next quarter's earnings?

Certara updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of 0.410-0.460 for the period, compared to the consensus estimate of 0.480. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $364.0 million.

When did Certara IPO?

Certara (CERT) raised $500 million in an IPO on Friday, December 11th 2020. The company issued 24,400,000 shares at $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

Who are Certara's major shareholders?

Certara's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.85%), Vanguard Group Inc. (7.85%), Mubadala Investment Co PJSC (6.02%), Baillie Gifford & Co. (5.58%), Clearbridge Investments LLC (2.59%) and Wasatch Advisors LP (2.50%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, Eran Broshy, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends
.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CERT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners